Loading patent…
OwnerDavid S. Peabody, Bryce Chackerianinventors
Estimating the term…
The present invention relates to a system and method for controlling peptide display valency on virus-like particles (VLPs), especially including MS2 or PP7 VLPs. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single RNA. Valency is controlled in immunogen (vaccine) production by providing a system that allows the production of large amounts of wild-type and low quantities of single-chain dimer coating proteins from a single RNA, allowing facile adjustment of display valency levels on bacteriophage VLPs, especially MS2 or PP7 VLPs over a wide range, from few than one—on average—to as many as ninety per particle. This facilitates the production of immunogens and vaccines, including VLPs exhibiting low valency. Nucleic acid constructs useful in the expression of virus-like particles are disclosed, comprised of a coat polypeptide of bacteriophage such as MS2 or PP7 modified by insertion of a heterologous peptide, optionally comprising a carbohydrate mimotope, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates bacteriphage mRNA.
A population of virus-like particles (VLPs), wherein each VLP is (a) a VLP of a RNA bacteriophage, wherein a portion of said VLP comprises (b) a single chain dimer of a coat polypeptide of said RNA bacteriophage modified by insertion of a heterologous peptide optionally comprising a carbohydarate mimotope, said dimer comprising an upstream and a downstream subunit, wherein said heterologous peptide is displayed on said VLP and (c) encapsidates said bacteriophage mRNA, said VLP exhibiting low valency.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An isolated transcription unit comprising:
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An isolated transcription unit comprising a bacteriophage promoter, a coding sequence of an RNA bacteriophage single chain coat polypeptide dimer having a site for insertion of a heterologous peptide optionally comprising a carbohydrate mimotope in said coding sequence in a downstream half of said dimer wherein said coding sequence comprises a codon-juggled sequence in an upstream half of said dimer and optionally, a bacteriophage terminator.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An immunogenic composition comprising one or more VLPs of a RNA bacteriophage of low valency and comprising a single chain dimer of the coat polypeptide of said phage, said coat polypeptide comprising an upstream subunit and a downstream subunit, wherein said downstream subunit is modified by insertion of an immunogenic heterologous peptide optionally comprising a carbohydrate mimotope, wherein no more than about 1 to 10 heterologous peptides are displayed on said VLP.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A nucleic acid construct comprising:
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
76-198. (canceled)
Dependencies are inferred from the claim text.